Linda Van Eldik, director of the UK Sanders-Brown Center on Aging, received $5.5 million from NIH and the Alzheimer's Drug Discovery Foundation. She developed a drug that is ready for its first round of testing in humans.
Research from the Sanders-Brown Center on Aging presented at the Society for Neuroscience annual meeting has identified two potential ways to predict vascular cognitive impairment and dementia (VCID) – the second leading cause of dementia behind Alzheimer's disease.
Results from a survey of more than 1,000 U.S. adults showed that while almost 80 percent of respondents were willing to volunteer for medical research, two-thirds didn't know how to get involved.
Scientists from four different institutions are working together to identify a biomarker for Alzheimer's Disease using mice that travel an 850-mile circuit to test the efficacy of special technology called Quest MRI.
The National Institutes of Health has awarded a five year, $2.88 million grant to a researcher at the Sanders-Brown Center on Aging to study a drug's potential to prevent Alzheimer's disease.
In a paper published in the Journal of Alzheimer's Disease, UK College of Medicine student Eseosa Ighodaro, Ph.D., addressed the numerous challenges associated with studying dementia in Blacks/African-Americans.
